Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802
Status:
Terminated
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
Phase 1, single-center, placebo-controlled, single-blind, first-in-human, single ascending
dose (SAD) study followed by a multiple-dose cohort in healthy male and female subjects.